FDA GLP-1 Compounding Crackdown 2026: What Patients Need to Know

While the FDA is reclassifying peptides to Category 1, simultaneously taking a dramatically different approach with GLP-1 drugs like semaglutide and tirzepatide. The FDA is aggressively cracking down on compounded GLP-1 medications, issuing over 30 warning letters to telehealth companies and compounding pharmacies. This creates a complex regulatory landscape where some compounds are being deregulated while others face tightening restrictions.

The Shortage List Removal: What Changed in February 2025

Until February 2025, semaglutide (Ozempic, Wegovy) was officially on the FDA's drug shortage list. This official designation meant that brand-name semaglutide was in short supply and difficult to obtain. Under compounding rules, when a drug is on the shortage list, pharmacies have more flexibility to compound versions of it, and the FDA is less aggressive in enforcement. The shortage designation created a legal pathway for telehealth companies and compounding pharmacies to prepare and sell semaglutide to patients.

However, in February 2025, semaglutide was removed from the official shortage list. The drug had become more available, supply chains had normalized, and manufacturers had increased production capacity. While this might seem like good news—the shortage is ending—it had major regulatory implications. Once removed from the shortage list, the FDA's justification for allowing widespread compounding evaporated. The drug was no longer in short supply, so permitting pharmacy compounding became harder to justify under regulatory frameworks designed to address supply disruptions.

The timing was striking. Just as the removal happened, the FDA began issuing the first of what would become 30+ warning letters to companies preparing compounded semaglutide. The message was clear: now that brand-name semaglutide is available, the FDA intends to restrict access to compounded versions. This creates a significant change for patients who had been using compounded GLP-1 drugs because they were cheaper or more accessible than brand-name products.

The 30+ FDA Warning Letters to GLP-1 Companies

Since early 2025, the FDA has issued over 30 warning letters to telehealth companies, online pharmacies, and compounding operations that prepare compounded GLP-1 drugs. These warning letters don't mean these companies are immediately shut down, but they do represent an official regulatory action warning them of violations and requesting corrective action. Companies that ignore warning letters face escalation: product seizures, injunctions, fines, and criminal prosecution.

The warning letters cite multiple violations and concerns. Most commonly, the FDA argues that compounding semaglutide and tirzepatide violates the law because these drugs are available commercially in sufficient quantity, making compounding unjustifiable under current regulations. The FDA also cites quality and safety concerns: lack of adequate sterility assurance, inadequate stability data, inadequate potency verification, and failure to follow Good Compounding Practices (GCP).

Some warning letters also address marketing claims and consumer protection issues. The FDA is particularly concerned about telehealth platforms that make exaggerated weight loss claims, fail to conduct adequate medical evaluations before prescribing, or market compounded GLP-1s as superior to brand-name products without justification. The FDA views these practices as both regulatory violations and consumer deception.

The affected companies range from large telehealth operations with thousands of patients to smaller compounding pharmacies that had started preparing GLP-1s. Some companies are fighting the warning letters in court, arguing they have the right to compound these drugs. Others are ceasing GLP-1 compounding operations to achieve compliance. The landscape is in flux, with uncertainty about which companies will survive regulatory challenges.

Quality and Safety Concerns With Compounded GLP-1s

The FDA's crackdown on compounded semaglutide and tirzepatide is not just regulatory overreach—there are legitimate quality and safety concerns. Several studies and investigations have found that compounded GLP-1 products vary significantly in actual drug content, with some containing less drug than claimed, others containing more, and some containing contaminants or impurities.

The challenge is that semaglutide is a complex peptide medication that requires sophisticated compounding to maintain stability and potency. It's not as simple as dissolving a powder in solution. Semaglutide is prone to degradation under various conditions, requires proper pH buffering, and must be handled with appropriate sterile technique to avoid contamination. Many compounding pharmacies, particularly those without extensive experience in peptide compounding, lack the expertise and equipment to properly prepare high-quality semaglutide formulations.

Additionally, while brand-name semaglutide is produced by Novo Nordisk in FDA-regulated facilities with extensive quality assurance, compounded versions don't receive the same level of scrutiny or standardization. Different compounding pharmacies use different techniques, different sources of raw materials, and different quality assurance procedures. A patient getting compounded semaglutide from one pharmacy might receive a very different product than a patient getting it from another pharmacy.

The FDA has documented cases where compounded semaglutide caused problems. Some patients experienced inadequate therapeutic effect because the compounded product had insufficient potency. Others experienced unexpected side effects or adverse reactions, potentially from contaminants or impurities. These safety incidents support the FDA's concern that some compounded GLP-1 products pose risks to patients. However, it's important to note that quality varies—some compounding pharmacies maintain high standards while others do not.

Novo Nordisk Lawsuits Against Compounding Pharmacies

Novo Nordisk, the manufacturer of Ozempic and Wegovy, has filed multiple lawsuits against companies preparing compounded semaglutide. The company argues on several legal grounds: patent infringement (claiming the process of compounding semaglutide infringes their patents), trademark infringement (companies labeling products as "semaglutide" are using their trademark without permission), and unfair competition (arguing that compounders are unfairly competing by avoiding the regulatory pathway Novo Nordisk navigated).

While Novo Nordisk's patent arguments are debated in legal circles, their trademark and unfair competition arguments are stronger. They own the trademark for "Ozempic" and "Wegovy," and they assert exclusive rights to prepare and distribute semaglutide formulations in the United States. Companies selling compounded semaglutide, they argue, are engaging in unlicensed manufacturing and unfair competition by offering cheaper alternatives that avoid Novo Nordisk's development costs and FDA approval processes.

Some legal observers note that Novo Nordisk's aggressive litigation strategy appears designed partly to protect market share and maintain high prices for their products. By eliminating cheaper compounded alternatives, Novo Nordisk can maintain premium pricing for brand-name Ozempic and Wegovy. This creates a tension between Novo Nordisk's profit interests and patients' access to affordable medications. However, Novo Nordisk also argues they have legitimate rights to their products and concerns about quality of compounded alternatives are valid.

Multiple lawsuits are working through the courts. Some compounding companies have settled, agreeing to stop preparing semaglutide. Others are fighting, arguing they have legal rights to compound available drugs under state pharmacy laws. The outcomes will significantly influence the future availability of compounded GLP-1 drugs. If Novo Nordisk prevails on patent or trademark grounds, it could substantially restrict compounding. If compounders prevail, it could validate their legal right to continue preparing these drugs.

Semaglutide vs Tirzepatide: Different Regulatory Paths

While both semaglutide and tirzepatide are GLP-1 medications (tirzepatide is technically a GLP-1/GIP receptor agonist), they face slightly different regulatory situations. Semaglutide has been on the market longer and is more established, while tirzepatide (Zepbound, Mounjaro) is newer and has been gaining popularity rapidly as a weight loss medication.

Semaglutide has been off the shortage list since February 2025, making it more available as a brand-name product. This availability supports the FDA's position that compounding is no longer necessary. Tirzepatide has also recently been removed from shortages in many regions, though there remain some supply constraints in certain markets. The FDA's aggressive stance applies to both compounds, though enforcement intensity may vary.

From a patient perspective, the regulatory pressure on compounded GLP-1s means patients have an incentive to transition to brand-name products if they can access them. This works in favor of larger pharmaceutical companies like Novo Nordisk and Eli Lilly (which manufactures tirzepatide), who benefit from reduced competition from compounders. For patients seeking affordable alternatives, the compounding crackdown is concerning as it reduces cost options.

Documented Patient Harm and Safety Incidents

Beyond quality testing data, there are documented reports of patient harm from compounded GLP-1 medications. Some patients have reported unexpected side effects, allergic reactions, or other adverse events associated with compounded products. While causality is difficult to prove (since these same side effects can occur with brand-name products), patterns suggest some compounded products are problematic.

In some cases, patients received products with inadequate potency, resulting in subtherapeutic dosing—the patient thought they were taking an effective dose but the actual drug content was too low. In other cases, patients reported that different batches from the same pharmacy seemed to have different strengths, suggesting inconsistent compounding quality. These experiences support the FDA's concern that unregulated compounding can harm patients through quality and consistency issues.

The FDA has also been concerned about telehealth companies that work with compounding pharmacies using inadequate medical evaluation processes. Some platforms allow patients to get GLP-1 prescriptions with minimal interaction with a healthcare provider, creating risk that patients inappropriate for GLP-1 therapy (those with contraindications or dangerous comorbidities) receive the medication. This represents a medical rather than just regulatory problem.

Transitioning From Compounded to Brand-Name GLP-1s

For patients currently using compounded semaglutide or tirzepatide who want to transition to brand-name products, several approaches are possible. The most important thing is to maintain continuity of care and avoid abrupt medication discontinuation, which can cause rebound weight gain and other issues.

First, work with your healthcare provider to discuss the regulatory situation and develop a transition plan. Your provider can help identify whether brand-name Ozempic, Wegovy, or other branded GLP-1 products would be appropriate for you and can facilitate a prescription. Many insurance plans cover these medications, though coverage varies. If cost is a concern, ask about patient assistance programs, discount cards, or discussing this with your insurance company.

Second, understand that the transition may involve adjusting doses or changing injection schedules. Compounded products and brand-name products may have different absorption kinetics, meaning the same dose may have different effects. Your provider should monitor you during the transition and adjust as needed. Be patient through this process—it typically takes 2-4 weeks to adjust to any medication change.

Third, if transitioning creates cost barriers, discuss this openly with your provider. They may have strategies to manage costs, know of assistance programs, or be able to work with insurance to facilitate coverage. Never abruptly stop a GLP-1 medication without medical guidance, as the rebound effects can be significant.

Future Legal Status of Compounded GLP-1 Drugs

The future of compounded GLP-1 drugs is uncertain but appears headed toward tighter restrictions. Several possible scenarios exist: (1) The FDA could formally place GLP-1 drugs in Category 2, explicitly banning compounding. This would be the most definitive action but would likely face legal challenges. (2) The FDA could continue using warning letters and enforcement actions to restrict access, gradually squeezing out compounding companies until few remain. (3) Novo Nordisk could win its lawsuits, establishing legal precedent that discourages compounding. (4) Congress could change laws to clarify whether compounding of available brand-name drugs is permissible.

Most likely, the trend will continue toward restriction. The FDA has signaled its position clearly through enforcement actions. Novo Nordisk's litigation is ongoing but appears to be succeeding in some cases. Compounding companies that try to continue face regulatory and legal challenges. For patients, this means that accessing compounded GLP-1s will become increasingly difficult, and transitioning to brand-name products is the safer, more sustainable path.

The contrast with peptide reclassification is striking. Peptides are moving toward greater access and legal availability, while GLP-1 drugs are moving toward restriction. This reflects different regulatory assessments of risk-benefit, different policy priorities, and different pharmaceutical company interests. Understanding these differences helps patients navigate a complex regulatory landscape.

What This Means for Patients Seeking Weight Loss or Metabolic Support

For patients seeking weight loss or metabolic support, the GLP-1 crackdown has several implications. First, if you're using compounded semaglutide, expect that continued access may become difficult. Plan now for a transition to brand-name Ozempic or Wegovy, or explore alternative approaches to weight management. Second, if you're seeking GLP-1 therapy for the first time, focus on brand-name products and work with licensed healthcare providers who can ensure you're a good candidate for the medication.

Third, be aware that compounded GLP-1 products may vary in quality. If you choose to use compounded products (understanding the regulatory risks), work with a reputable compounding pharmacy that can provide evidence of their quality assurance practices and testing procedures. Ask about potency verification, sterility assurance, and stability data. However, understand that using compounded GLP-1s exposes you to regulatory risk—if the FDA takes action against your pharmacy, you may lose access suddenly.

Fourth, consider that the pharmaceutical industry's interests and FDA policy don't always perfectly align with patient interests. While FDA concerns about quality are legitimate, their enforcement also benefits Novo Nordisk financially by eliminating competition and allowing them to maintain premium pricing. As a patient, being aware of these dynamics helps you make informed decisions about your care.